Assessment Report

The clinical effectiveness and cost effectiveness of strontium ranelate for the prevention of osteoporotic fragility fractures in postmenopausal women

Dear Dr Fuller,

We welcome the Assessment Report on “The clinical effectiveness and cost effectiveness of strontium ranelate for the prevention of osteoporotic fragility fractures in postmenopausal women” and look forward to a smooth process and a timely issuance of the final Guidance on primary and secondary prevention of osteoporotic fragility fractures in postmenopausal women. The Alliance for Better Bone Health has one general comment:

‘Why is there an identification strategy mentioned in Section 4.2 of this Assessment Report? This is a deviation from the original scope and indeed from the purpose of an Assessment Report. Surely such a strategy would form part of a Guideline not a Guidance?

Yours sincerely, on behalf of the Alliance for Better Bone Health and Procter & Gamble Pharmaceuticals,

Dr Heert Eijkman
Medical Director – UK/NL/Ireland
Procter & Gamble Pharmaceuticals
Rusham Park
Whitehall Lane
Egham
TW20 9NW

Dr Alan Collins
NICE Project Manager
Procter & Gamble Pharmaceuticals
Rusham Park
Whitehall Lane
Egham
TW20 9NW

Mr Mike Baldwin
Head of Health Technology Appraisals
Sanofi-aventis
One Onslow Street
Guildford
Surrey
GU1 4YS